Epitel, a leader in AI technology for patient-centered brain health solutions, has announced the addition of wearables industry pioneer Ken Nelson to its board of directors. With his expertise in digital health, medical devices and remote patient monitoring, Nelson will play a critical role in leading Epitel's growth as the company continues to transform the brain monitoring landscape with AI/ML and wearable EEG technology. Ken Nelson brings a wealth of knowledge with over 20 years of experience and extensive expertise in building teams and leading commercial efforts to create disruptive technologies in the wearables and remote patient monitoring industries.

His extensive commercial leadership experience in digital health and remote cardiac patient monitoring includes a key role in building infrastructure for top market players. His notable achievements include Global Sales Vice President Biotelemetry, Irhythm Vice -President of Sales and Marketing and Bardy Diagnostics Chief Business Worker. Recently, he was a manager of digital health, diagnosis and supervision in biotronics. His career highlights include leading commercial efforts that led to successful IPOs and acquisitions, including the $2.8 billion acquisition of BioTelemetry by Philips and the $450 million acquisition of Bardy Diagnostics by HillRom/Baxter.

"Ken Nelson has extensive experience and a proven track record in the medical technology and digital health industries," said Epitel CEO Mark Lehmkuhle. "His strategic insight and leadership will be invaluable as we continue to develop AI-powered brain health solutions and expand our impact on patient care. We are excited to welcome Ken to our Board of Directors."

Nelson is currently a partner at Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, the world's largest MedTech and digital health startup accelerator. In addition, he is Chairman of CardiaCare and an active board member of HeartBeam (NASDAQ: BEAT ), Happitech and several other disruptive cardiac digital health and MedTech startups.

Nelson is also involved in advisory boards and planning committees for SmartCardia, HeartX, HRX (Heart Rhythm Society's Digital Health Summit), as well as the American Heart Association's Health Technology Innovation Business Advisory Board and the Heart & Brain Accelerator. "With Epitel's innovative FDA-approved products coming to market, we will fundamentally change the standard of care for brain health monitoring, first focusing on seizures and monitoring in patients with epilepsy, and then expanding to EEG and other areas of the brain." said Nelson Health Monitoring I understand how we can transform digital heart health and EKG remote patient monitoring into a multi-billion dollar industry, which is a big part of Epitel's roadmap to follow and lead in EEG monitoring.

Nelson joins a strong advisory team that includes Genoa Ventures CEOs Mark Lehmkuhle, Vikram Chaudhery and Catalyst Health Ventures Josh Phillips.